Log In
Print this Print this

Cypher Select

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionSirolimus-eluting stent
Molecular Target FK506 binding protein 1A 12kDa (FKBP1A) (FKBP12)
Mechanism of ActionMammalian target of rapamycin (mTOR) kinase inhibitor
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentMarketed
Standard IndicationIschemia / reperfusion injury
Indication DetailsTreat severe claudication and critical limb ischemia (CLI) of infrapopliteal lesions
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today